In this context it should be considered that the European Court of justice has recently clarified the situation for "magistral formulae" defined as "any medicinal product prepared in a pharmacy in accordance with a medical prescription for an individual patient" (The European Court of Justice. Document 62013CJ0544 and Judgment of the Court (Third Chamber) of 16 July 2015) . The European Court of Justice specified that "[such a preparation] must of necessity be prepared on the basis of a prior prescription issued by a professional person qualified to do so". This prescription must, in addition "be 'for an individual patient'" and "that patient must be identified before the medicinal product is produced and it must be produced specifically for that patient". In a simpler wording such preparations have to be "extemporaneously". It was also stated that "that the exception provided for in that provision can only concern situations in which the doctor considers that the state of health of his individual patients requires that a medicinal product be administered for which there is no authorised equivalent on the national market or which is unavailable on that market", clearly excluding competition with licensed medicinal products. Also specifically excluded in this ruling were preparations "on the basis of the needs known in advance, to be used in emergency departments and, in any event, on the basis of orders placed before a specified patient had been identified" and "Preparations prepared and delivered to non-hospital pharmacies, on the basis of a 'subscription' , even if an 'initial medical prescription' was drawn up for each specific patient". The Court ruled that the aforementioned preparations were not "magistral" but medicinal products "prepared industrially or manufactured by a method involving an industrial process….. Such a process is characterised in general by a succession of operations, which may, in particular, be mechanical or chemical, in order to obtain a significant quantity of a standardised product."
Translated to the preparation of PET radiopharmaceuticals it could be derived from this ruling, that PET preparations can be considered in many situations as being "magistral". Typically a type of prescriptions by the physician referring an individual patient to Nuclear Medicine is provided, for whom the PET radiopharmaceutical is prepared, possibly with the exemption of FDG production in large departments where the preparation is made without necessarily always knowing the individual patient, and especially if it is shipped to different sites. However in this context also "officinal preparations" could be considered, in case a monograph for the radiopharmaceutical is available (which today is the case for most routinely used PET radiopharmaceuticals).
At the bottom line the discussion focusses on the question, are we "preparing" or "manufacturing" radiopharmaceuticals. If they are (extemporaneously, on a small scale, locally) prepared, exemptions as stated above may apply, whereas in they are (industrially) manufactured, the framework of GMP implemented within a manufacturing authorisation should be applied. The European Pharmacopeia (Ph. Eur.) as a legal basis for almost all European countries have tried to clarify what they see as "preparation", in the monograph on "Pharmaceutical Preparations" (Pharmaceutical preparations. Monograph N°2619) the following definition can be found: "the 'manufacture' of unlicensed pharmaceutical preparations in pharmacies or other healthcare establishments (the term 'preparation' is used instead of 'manufacture' in order clearly to distinguish it from the industrial manufacture of licensed pharmaceutical preparations)". Even more specifically the term radiopharmaceutical preparation is used in the General text 5.19 of the Ph. Eur. and explicitly includes kit-based preparations as well as unlicensed preparations for PET and SPECT.
Applying this definition to radiopharmaceuticals underlines the clear distinction between the industrial manufacturing in a framework of "licensing" i.e. marketing authorisation or clinical trials aiming at a marketing authorisation versus the local, extemporaneous preparation of radiopharmaceuticals being it for patient diagnosis or within the framework of a local clinical trial.
Discussions with regulatory bodies should try to stress this point, giving the Nuclear Medicine community the possibility to provide required (novel or established) radiopharmaceuticals for patients needs and to bring the speciality forward towards the times of personalized medicine, tailor-made for patients need that deserve the best medicines, being radioactive or not. Any preparation to be reconstituted or combined with radionuclides in the final radiopharmaceutical, usually prior to its administration. Magistral prepared in a pharmacy in accordance with a medical prescription for an individual patient Manufacture larger scale commercial/industrial production; all operations of purchase of material and products, Production, Quality Control, release, storage, distribution of medicinal products and the related control (from European Pharmacopoeia: Pharmaceutical Preparations) Officinal prepared in a pharmacy in accordance with the prescriptions of a pharmacopoeia and intended to be supplied directly to the patients served by the pharmacy in question Parenteral sterile preparations intended for administration by injection, infusion or implantation into the human or animal body PET Positron Emission Tomography PIC/S Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme Preparation small scale non-industrial production; the 'manufacture' of unlicensed pharmaceutical preparations in pharmacies or other healthcare establishments (from European Pharmacopoeia: Pharmaceutical Preparation) Radiopharmaceutical Any medicinal product which, when ready for use, contains one or more radionuclides (radioactive isotopes) included for a medicinal purpose.
